Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial.
Schmidt M, Nitz U, Reimer T, Schmatloch S, Graf H, Just M, Stickeler E, Untch M, Runnebaum I, Belau A, Huober J, Jackisch C, Hofmann M, Krocker J, Nekljudova V, Loibl S, GBG/AGO-B, NOGGO/WSG study groups. Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial. Eur J Cancer 2023; 194:113324.
07.09.2023Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial.
07.09.2023Eur J Cancer 2023; 194:113324
Schmidt Marcus, Nitz Ulrike A, Reimer Toralf, Schmatloch Sabine, Graf Heiko, Just Marianne, Stickeler Elmar, Untch Michael, Runnebaum Ingo B, Belau Antje, Huober Jens, Jackisch Christian, Hofmann Manfred, Krocker Jutta, Nekljudova Valentina, Loibl Sibylle, GBG/AGO-B, NOGGO/WSG study groups
Cellular and metabolic characteristics of pre-leukemic hematopoietic progenitors with GATA2 haploinsufficiency.
Rein A, Geron I, Kugler E, Fishman H, Gottlieb E, Abramovich I, Giladi A, Amit I, Mulet-Lazaro R, Delwel R, Gröschel S, Levin-Zaidman S, Dezorella N, Holdengreber V, Rao T, Yacobovich J, Steinberg-Shemer O, Huang Q, Tan Y, Chen S, Izraeli S, Birger Y. Cellular and metabolic characteristics of pre-leukemic hematopoietic progenitors with GATA2 haploinsufficiency. Haematologica 2023; 108:2316-2330.
01.09.2023Cellular and metabolic characteristics of pre-leukemic hematopoietic progenitors with GATA2 haploinsufficiency.
01.09.2023Haematologica 2023; 108:2316-2330
Rein Avigail, Geron Ifat, Kugler Eitan, Fishman Hila, Gottlieb Eyal, Abramovich Ifat, Giladi Amir, Amit Ido, Mulet-Lazaro Roger, Delwel Ruud, Gröschel Stefan, Levin-Zaidman Smadar, Dezorella Nili, Holdengreber Vered, Rao Tata Nageswara, Yacobovich Joanne, Steinberg-Shemer Orna, Huang Qiu-Hua, Tan Yun, Chen Sai-Juan, Izraeli Shai, Birger Yehudit
Neuropathies related to hepatitis E virus infection: A prospective, matched case-control study.
Ripellino P, Lascano A, Scheidegger O, Schilg-Hafer L, Schreiner B, Tsouni P, Vicino A, Peyer A, Humm A, Décard B, Pianezzi E, Zezza G, Sparasci D, Hundsberger T, Dietmann A, Jung H, Kuntzer T, Wilder-Smith E, Martinetti-Lucchini G, Petrini O, Fontana S, Gowland P, Niederhauser C, Gobbi C. Neuropathies related to hepatitis E virus infection: A prospective, matched case-control study. Eur J Neurol 2023; 31:e16030.
25.08.2023Neuropathies related to hepatitis E virus infection: A prospective, matched case-control study.
25.08.2023Eur J Neurol 2023; 31:e16030
Ripellino Paolo, Lascano Agustina Maria, Scheidegger Olivier, Schilg-Hafer Lenka, Schreiner Bettina, Tsouni Pinelopi, Vicino Alex, Peyer Anne-Kathrin, Humm Andrea Monika, Décard Bernhard Friedrich, Pianezzi Enea, Zezza Giulia, Sparasci Davide, Hundsberger Thomas, Dietmann Anelia, Jung Hans H, Kuntzer Thierry, Wilder-Smith Einar, Martinetti-Lucchini Gladys, Petrini Orlando, Fontana Stefano, Gowland Peter, Niederhauser Christoph, Gobbi Claudio
Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections.
Schmitt C, Hoefsmit E, Fangmeier T, Kramer N, Kabakci C, González-Navajas J, Versluis J, Compter A, Harrer T, Mijočević H, Schubert S, Hundsberger T, Menzies A, Scolyer R, Long G, French L, Blank C, Heinzerling L. Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections. Cancer Immunol Immunother 2023
22.08.2023Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections.
22.08.2023Cancer Immunol Immunother 2023
Schmitt Christina, Hoefsmit E P, Fangmeier T, Kramer N, Kabakci C, González-Navajas Jose M, Versluis Judith M, Compter Annette, Harrer T, Mijočević H, Schubert Steffen, Hundsberger Thomas, Menzies A M, Scolyer Richard A, Long Georgina V, French Lars Einar, Blank Christian U, Heinzerling Lucie M
Extended Adjuvant Endocrine Therapy in Early Breast Cancer Patients-Review and Perspectives.
Bekes I, Huober J. Extended Adjuvant Endocrine Therapy in Early Breast Cancer Patients-Review and Perspectives. Cancers (Basel) 2023; 15
21.08.2023Extended Adjuvant Endocrine Therapy in Early Breast Cancer Patients-Review and Perspectives.
21.08.2023Cancers (Basel) 2023; 15
Bekes Inga, Huober Jens
Genetic alterations and MRD refine risk assessment within KMT2A-rearranged B-cell precursor ALL in adult: a GRAALL study.
Kim R, Bergugnat H, Pastoret C, Pasquier F, Raffoux E, Larcher L, Passet M, Grardel N, Delabesse E, Kubetzko S, Caye-Eude A, Meyer C, Marschalek R, Lafage-Pochitaloff M, Thiebaut-Bertrand A, Balsat M, Escoffre-Barbe M, Blum S, Baumann M, Banos A, Straetmans N, Gallego-Hernanz M, Chalandon Y, Graux C, Soulier J, Leguay T, Hunault-Berger M, Huguet F, Lhéritier V, Dombret H, Boissel N, Clappier E. Genetic alterations and MRD refine risk assessment within KMT2A-rearranged B-cell precursor ALL in adult: a GRAALL study. Blood 2023
18.08.2023Genetic alterations and MRD refine risk assessment within KMT2A-rearranged B-cell precursor ALL in adult: a GRAALL study.
18.08.2023Blood 2023
Kim Rathana, Bergugnat Hugo, Pastoret Cedric, Pasquier Florence, Raffoux Emmanuel, Larcher Lise, Passet Marie, Grardel Nathalie, Delabesse Eric, Kubetzko Susanne, Caye-Eude Aurélie, Meyer Claus, Marschalek Rolf, Lafage-Pochitaloff Marina, Thiebaut-Bertrand Anne, Balsat Marie, Escoffre-Barbe Martine, Blum Sabine, Baumann Michael, Banos Anne, Straetmans Nicole, Gallego-Hernanz Maria-Pilar, Chalandon Yves, Graux Carlos, Soulier Jean, Leguay Thibaut, Hunault-Berger Mathilde, Huguet Françoise, Lhéritier Véronique, Dombret Hervé, Boissel Nicolas, Clappier Emmanuelle
Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
Cathomas R, Rothschild S, Hayoz S, Bubendorf L, Özdemir B, Kiss B, Erdmann A, Aeppli S, Mach N, Strebel R, Hadaschik B, Berthold D, John H, Zihler D, Schmid M, Alborelli I, Schneider M, Musilova J, Spahn M, Petrausch U. Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17. J Clin Oncol 2023; 41:5131-5139.
17.08.2023Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
17.08.2023J Clin Oncol 2023; 41:5131-5139
Cathomas Richard, Rothschild Sacha I, Hayoz Stefanie, Bubendorf Lukas, Özdemir Berna C, Kiss Bernhard, Erdmann Andreas, Aeppli Stefanie, Mach Nicolas, Strebel Räto T, Hadaschik Boris, Berthold Dominik R, John Hubert, Zihler Deborah, Schmid Mathias, Alborelli Ilaria, Schneider Martina, Musilova Jana, Spahn Martin, Petrausch Ulf
Quality criteria for pediatric oncology centers: A systematic literature review.
Schladerer S, Otth M, Scheinemann K. Quality criteria for pediatric oncology centers: A systematic literature review. Cancer Med 2023; 12:18999-19012.
16.08.2023Quality criteria for pediatric oncology centers: A systematic literature review.
16.08.2023Cancer Med 2023; 12:18999-19012
Schladerer Sarah P, Otth Maria, Scheinemann Katrin
Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer.
Templeton A, Omlin A, Berthold D, Beyer J, Burger I, Eberli D, Engeler D, Fankhauser C, Fischer S, Gillessen S, Nicolas G, Kroeze S, Lorch A, Müntener M, Papachristofilou A, Schäfer N, Seiler D, Stenner-Liewen F, Tsantoulis P, Vlajnic T, Zilli T, Zwahlen D, Cathomas R. Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer. Swiss Med Wkly 2023; 153:40108.
15.08.2023Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer.
15.08.2023Swiss Med Wkly 2023; 153:40108
Templeton Arnoud J, Omlin Aurelius, Berthold Dominik R, Beyer Jörg, Burger Irene A, Eberli Daniel, Engeler Daniel, Fankhauser Christian Daniel, Fischer Stefanie, Gillessen Silke, Nicolas Guillaume, Kroeze Stephanie G C, Lorch Anja, Müntener Michael, Papachristofilou Alexandros, Schäfer Niklaus G, Seiler Daniel, Stenner-Liewen Frank, Tsantoulis Petros, Vlajnic Tatjana, Zilli Thomas, Zwahlen Daniel Rudolf, Cathomas Richard
Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma.
Bandini C, Mereu E, Paradzik T, Labrador M, Maccagno M, Cumerlato M, Oreglia F, Prever L, Manicardi V, Taiana E, Ronchetti D, D'Agostino M, Gay F, Larocca A, Besse L, Merlo G, Hirsch E, Ciarrocchi A, Inghirami G, Neri A, Piva R. Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma. Exp Hematol Oncol 2023; 12:71.
10.08.2023Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma.
10.08.2023Exp Hematol Oncol 2023; 12:71
Bandini Cecilia, Mereu Elisabetta, Paradzik Tina, Labrador Maria, Maccagno Monica, Cumerlato Michela, Oreglia Federico, Prever Lorenzo, Manicardi Veronica, Taiana Elisa, Ronchetti Domenica, D'Agostino Mattia, Gay Francesca, Larocca Alessandra, Besse Lenka, Merlo Giorgio Roberto, Hirsch Emilio, Ciarrocchi Alessia, Inghirami Giorgio Ga, Neri Antonino, Piva Roberto
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Huober J, Weder P, Ribi K, Thürlimann B, Thery J, Li Q, Vanlemmens L, Guiu S, Brain E, Grenier J, Dalenc F, Levy C, Savoye A, Müller A, Membrez-Antonioli V, Gerard M, Lemonnier J, Hawle H, Dietrich D, Boven E, Bonnefoi H, Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group. Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 2023
10.08.2023Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
10.08.2023JAMA Oncol 2023
Huober Jens, Weder Patrik, Ribi Karin, Thürlimann Beat, Thery Jean-Christophe, Li Qiyu, Vanlemmens Laurence, Guiu Séverine, Brain Etienne, Grenier Julien, Dalenc Florence, Levy Christelle, Savoye Aude-Marie, Müller Andreas S, Membrez-Antonioli Véronique, Gerard Marie-Aline, Lemonnier Jérôme, Hawle Hanne, Dietrich Daniel, Boven Epie, Bonnefoi Hervé R, Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group
Swiss Survey on current practices and opinions on clinical constellations triggering the search for PNH clones.
Rovó A, Gavillet M, Drexler B, Keller P, Schneider J, Colucci G, Beauverd Y, van Dorland H, Pollak M, Schmidt A, De Gottardi A, Bissig M, Lehmann T, Duchosal M, Zeerleder S. Swiss Survey on current practices and opinions on clinical constellations triggering the search for PNH clones. Front Med (Lausanne) 2023; 10:1200431.
26.07.2023Swiss Survey on current practices and opinions on clinical constellations triggering the search for PNH clones.
26.07.2023Front Med (Lausanne) 2023; 10:1200431
Rovó Alicia, Gavillet Mathilde, Drexler Beatrice, Keller Peter M, Schneider Jenny Sarah, Colucci Giuseppe, Beauverd Yan, van Dorland Hendrika Anette, Pollak Matthias, Schmidt Adrian, De Gottardi Andrea, Bissig Marina, Lehmann Thomas, Duchosal Michel A, Zeerleder Sacha
Immune checkpoint inhibitors induced side effects of the peripheral nervous system.
Hundsberger T, Schreiner B, Roth P. Immune checkpoint inhibitors induced side effects of the peripheral nervous system. Curr Opin Neurol 2023; 36:427-431.
24.07.2023Immune checkpoint inhibitors induced side effects of the peripheral nervous system.
24.07.2023Curr Opin Neurol 2023; 36:427-431
Hundsberger Thomas, Schreiner Bettina, Roth Patrick
EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy.
Amaral T, Pop O, Chatziioannou E, Sinnberg T, Niessner H, Zhao J, Ring S, Jörger M, Schroeder C, Armeanu-Ebinger S, Cozzio A, Leiter U, Thomas I, Jochum W, Garbe C, Forchhammer S, Levesque M, Mangana J, Hölzel M, Dummer R, Schürch C, Forschner A, Flatz L. EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy. J Am Acad Dermatol 2023; 89:1072-1074.
22.07.2023EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy.
22.07.2023J Am Acad Dermatol 2023; 89:1072-1074
Amaral Teresa, Pop Oltin Tiberiu, Chatziioannou Eftychia, Sinnberg Tobias, Niessner Heike, Zhao Jing Hua, Ring Sandra Stephanie, Jörger Markus, Schroeder Christopher, Armeanu-Ebinger Sorin, Cozzio Antonio, Leiter Ulrike, Thomas Ioannis, Jochum Wolfram, Garbe Claus, Forchhammer Stephan, Levesque Mitchell Paul, Mangana Joanna, Hölzel Michael, Dummer Reinhard, Schürch Christian M, Forschner Andrea, Flatz Lukas
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.
König D, Savic Prince S, Hayoz S, Zens P, Berezowska S, Jochum W, Stauffer E, Braunersreuther V, Trachsel B, Thierstein S, Mark M, Schmid S, Curioni-Fontecedro A, Addeo A, Schmitt-Opitz I, Guckenberger M, Früh M, Betticher D, Ris H, Stupp R, Rothschild S, Bubendorf L, Pless M. Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14. ESMO Open 2023; 8:101595.
11.07.2023Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.
11.07.2023ESMO Open 2023; 8:101595
König Dietmar-Pierree, Savic Prince Spasenija, Hayoz Stefanie, Zens P, Berezowska Sabina, Jochum Wolfram, Stauffer Edouard, Braunersreuther V, Trachsel B, Thierstein Sandra, Mark Michael Thomas, Schmid Sebastian M, Curioni-Fontecedro Alessandra, Addeo Alfredo, Schmitt-Opitz Isabelle, Guckenberger Matthias, Früh Martin, Betticher Daniel C, Ris H B, Stupp Roger, Rothschild Sacha I, Bubendorf Lukas, Pless Miklos
The Absolute Monocyte Count at Diagnosis Affects Prognosis in Myelodysplastic Syndromes Independently of the IPSS-R Risk Score.
Silzle T, Blum S, Kasprzak A, Nachtkamp K, Rudelius M, Hildebrandt B, Götze K, Gattermann N, Lauseker M, Germing U. The Absolute Monocyte Count at Diagnosis Affects Prognosis in Myelodysplastic Syndromes Independently of the IPSS-R Risk Score. Cancers (Basel) 2023; 15
11.07.2023The Absolute Monocyte Count at Diagnosis Affects Prognosis in Myelodysplastic Syndromes Independently of the IPSS-R Risk Score.
11.07.2023Cancers (Basel) 2023; 15
Silzle Tobias, Blum Sabine, Kasprzak Annika, Nachtkamp Kathrin, Rudelius Martina, Hildebrandt Barbara, Götze Katharina S, Gattermann Norbert, Lauseker Michael, Germing Ulrich
Cerebrospinal Fluid HIV-1 Escape in Patients With Neurocognitive Symptoms: Pooled Data From a Neuro-HIV Platform and the NAMACO Study.
Filippidis P, Damas J, Viala B, Assal F, Tshikung O, Tarr P, Derfuss T, Oberholzer M, Jelcic I, Hundsberger T, Sacco L, Cavassini M, Du Pasquier R, Darling K, NAMACO Study Group, Swiss HIV Cohort Study. Cerebrospinal Fluid HIV-1 Escape in Patients With Neurocognitive Symptoms: Pooled Data From a Neuro-HIV Platform and the NAMACO Study. J Acquir Immune Defic Syndr 2023; 93:219-228.
01.07.2023Cerebrospinal Fluid HIV-1 Escape in Patients With Neurocognitive Symptoms: Pooled Data From a Neuro-HIV Platform and the NAMACO Study.
01.07.2023J Acquir Immune Defic Syndr 2023; 93:219-228
Filippidis Paraskevas, Damas José, Viala Benjamin, Assal Frédéric, Tshikung Olivier Nawej, Tarr Philip X00a0 E, Derfuss Tobias, Oberholzer Michael, Jelcic Ilijas, Hundsberger Thomas, Sacco Leonardo, Cavassini Matthias, Du Pasquier Renaud A, Darling Katharine Elizabeth Anna, NAMACO Study Group, Swiss HIV Cohort Study
Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).
Tausch C, Däster K, Hayoz S, Matrai Z, Fitzal F, Henke G, Zwahlen D, Gruber G, Zimmermann F, Andreozzi M, Goldschmidt M, Schulz C, Maggi N, Saccilotto R, Heidinger M, Müller A, Tampaki E, Bjelic-Radisic V, Sávolt Á, Smanykó V, Hagen D, Müller D, Gnant M, Loibl S, Markellou P, Bekes I, Egle D, Ruhstaller T, Muenst S, Kümmel S, Vrieling C, Satler R, Becciolini C, Bucher S, Kurzeder C, Simonson C, Fehr P, Gabriel N, Maráz R, Sarlos D, Dedes K, Leo C, Berclaz G, Fansa H, Hager C, Reisenberger K, Singer C, Montagna G, Reitsamer R, Winkler J, Lam G, Fehr M, Naydina T, Kohlik M, Clerc K, Ostapenko V, Lelièvre L, Heil J, Knauer M, Weber W. Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). Breast Cancer Res Treat 2023; 201:215-225.
25.06.2023Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).
25.06.2023Breast Cancer Res Treat 2023; 201:215-225
Tausch Christoph, Däster Kavitha, Hayoz Stefanie, Matrai Zoltan, Fitzal Florian, Henke Guido, Zwahlen Daniel Rudolf, Gruber Günther, Zimmermann Frank, Andreozzi Mariacarla, Goldschmidt Maite, Schulz Christina-Alexandra, Maggi Nadia, Saccilotto Ramon, Heidinger Martin, Müller Andreas S, Tampaki Ekaterini Christina, Bjelic-Radisic Vesna, Sávolt Ákos, Smanykó Viktor, Hagen Daniela, Müller Dieter J, Gnant Michael, Loibl Sibylle, Markellou Pagona, Bekes Inga, Egle Daniel, Ruhstaller Thomas, Muenst Simone, Kümmel Sherko, Vrieling Conny, Satler Rok, Becciolini Charles, Bucher Susanne, Kurzeder Christian, Simonson Colin, Fehr Peter Martin, Gabriel Natalie, Maráz Robert, Sarlos Dimitri, Dedes Konstantin Johannes, Leo Cornelia, Berclaz Gilles, Fansa Hisham, Hager Christopher, Reisenberger Klaus, Singer Christian F, Montagna Giacomo, Reitsamer Roland, Winkler Jelena, Lam Giang Thanh, Fehr Mathias Konrad, Naydina Tatiana, Kohlik Magdalena, Clerc Karine, Ostapenko Valerijus, Lelièvre Loic, Heil Jörg, Knauer Michael, Weber Walter Paul
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.
Hilberink J, van Zeventer I, Chitu D, Pabst T, Klein S, Stussi G, Griskevicius L, Valk P, Cloos J, van de Loosdrecht A, Breems D, van Lammeren-Venema D, Boersma R, Jongen-Lavrencic M, Fehr M, Hoogendoorn M, Manz M, Söhne M, van Marwijk Kooy R, Deeren D, van der Poel M, Legdeur M, Tick L, Chalandon Y, Ammatuna E, Blum S, Löwenberg B, Ossenkoppele G, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK), Huls G. Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine. Blood Cancer J 2023; 13:93.
19.06.2023Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.
19.06.2023Blood Cancer J 2023; 13:93
Hilberink Jacobien R, van Zeventer Isabelle A, Chitu Dana A, Pabst Thomas, Klein Saskia K, Stussi Georg, Griskevicius Laimonas, Valk Peter J M, Cloos Jacqueline, van de Loosdrecht Arjan A, Breems Dimitri A, van Lammeren-Venema Daniëlle, Boersma Rinske, Jongen-Lavrencic Mojca, Fehr Martin, Hoogendoorn Mels, Manz Markus G, Söhne Maaike, van Marwijk Kooy Rien, Deeren Dries, van der Poel Marjolein W M, Legdeur Marie-Cecile J C, Tick Lidwine W, Chalandon Yves, Ammatuna Emanuele, Blum Sabine, Löwenberg Bob, Ossenkoppele Gert J, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK), Huls Gerwin
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023.
Thill M, Kolberg-Liedtke C, Albert U, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, Dall P, Ditsch N, Fallenberg E, Fasching P, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Hartkopf A, Heil J, Huober J, Jackisch C, Kreipe H, Krug D, Kühn T, Kümmel S, Loibl S, Luftner D, Lux M, Maass N, Mundhenke C, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H, Solbach C, Solomayer E, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Müller V, Wuerstlein R, Janni W, Park-Simon T. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023. Breast Care (Basel) 2023; 18:306-315.
16.06.2023AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023.
16.06.2023Breast Care (Basel) 2023; 18:306-315
Thill Marc, Kolberg-Liedtke Cornelia, Albert Ute-Susann, Banys-Paluchowski Maggie, Bauerfeind Ingo, Blohmer Jens-Uwe, Budach Wilfried, Dall Peter, Ditsch Nina, Fallenberg Eva Maria, Fasching Peter Andreas, Fehm Tanja N, Friedrich Michael, Gerber Bernd, Gluz Oleg, Harbeck Nadia, Hartkopf Andreas D, Heil Jörg, Huober Jens, Jackisch Christian, Kreipe Hans-Heinrich, Krug David, Kühn Thorsten, Kümmel Sherko, Loibl Sibylle, Luftner Diana, Lux Michael Patrick, Maass Nicolai, Mundhenke Christoph, Reimer Toralf, Rhiem Kerstin, Rody Achim, Schmidt Marcus, Schneeweiss Andreas, Schütz Florian, Sinn Hans-Peter, Solbach Christine, Solomayer Erich-Franz, Stickeler Elmar, Thomssen Christoph, Untch Michael, Witzel Isabell, Wöckel Achim, Müller Volkmar, Wuerstlein Rachel, Janni Wolfgang, Park-Simon Tjoung-Won